CBD and cancer — it’s a loaded topic. A lot of vague, misleading information gets thrown around.

Some claim cannabinoids are the cure we’ve been looking for while others maintain it’s all speculation. But what do we actually know?

Unfortunately, not as much as we wish. Drug prohibition severely limited research regarding cannabis as a medicine. Even to this day, scientists struggle to receive approval from government agencies when it comes to looking into cannabis’ medical properties.

Still, that’s not to say there’s nothing out there. Throughout this article, we’re going to share with you what we do know about cannabidiol (CBD) and cancer. From there, we’re going to give you our honest, educated opinion about using CBD as part of your treatment.

It can be difficult to find good buys in the cannabis industry, especially since a lot of the focus is on industry leaders Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:CGC). That means investors may overlook other, smaller stocks that may not get as much attention but that offer good value. Below are three stocks in that category that could be good buys this year as the industry matures.

Without the rigorous controls that exist at an approved professional cultivation facility, it’s easy to make a mistake — and make yourself sick in the process.

In the rare event of cannabis contamination, marijuana’s health benefits can turn into health hazards.

The dynamics of the cannabis tech sector are unlike any other. Three years ago, as talk of legalization increased in North America, the sector exploded with mega-investments by venture capital funds, including some established especially for the sector, like Snoop Dog’s Casa Verde or Mark Anderson’s Vice Ventures. In 2018 alone, $2.6 billion in investments poured into the sector.

Over the long run, the cannabis industry could provide a smorgasbord of growth for investors. Having already tripled global sales between 2014 and 2018, Wall Street has weighed in and expects worldwide weed sales to catapult by another 400% to 1,800% by 2030. The wide margin in Wall Street's forecast reflects the uncertainties associated with launching a high-growth yet still-nascent industry.

Yet at the same time, near-term prospects for the industry aren't as bright. It was long suspected that not every pot stock was going to be a winner, and we've begun to see a shakeout taking place throughout North America.

While it’s illegal for him to prescribe medical marijuana, Dr. David Sine has found a sweet spot for his patients in letting them know all of the options available.

Dr. David Sine’s passion for decreasing pain and creating new pathways to wellness in palliative care and hospice has only increased in the past eight years. A pioneer in pediatric care, Dr. Sine focuses on children who have life-limiting illnesses and need a higher level of attention to help them recover or transition on. 

It’s looking like Thunderbirds are go for a medical cannabis insomnia product developed by Zelira Therapeutics (ASX:ZLD).

In case you’re wondering who Zelira is, you might recognise it by its previous name – Zelda Therapeutics. The name change came about after a merger with the USA’s Ilera Therapeutics LLC was finalised late last year.

The trend of infusing various beverages continues to grow, but to know if you want to sell these types of products in your shop, you first need to understand the trends and why they appeal to consumers.

For the last few years, consumers have been gravitating towards edibles. This is true for both the THC and CBD markets, and it applies to all age ranges. It also includes more than just food, with CBD beverages making up for a large part of the market demand.

Cannabidiol or CBD products have hit shelves in droves since Congress made hemp legal with the 2018 Farm Bill. Derived from the hemp plant, advocates herald CBD as a potentially strong treatment for issues such as inflammation and pain management.

But what if there was a cannabinoid that did the job even better?

That’s the claim, by some, for cannabigerol or CBG. According to New Jersey.com, CBG has been called “a better anti-inflammatory and anti-anxiety treatment than CBD or marijuana,” partly because it’s less likely to make the user groggy or paranoid.

Since the signing of the 2018 Farm Bill in December, 2018, significant attention has been paid to the differences between hemp and marijuana. Most reasoning comes down to the level of THC as the differentiating factor. But there is so much more going on here.

Hemp and marijuana are, in fact, two different plants in the same species of three different types of marijuana: cannabis sativa, cannabis indica, and cannabis ruderalis.